Welcome to our dedicated page for Pds Biotechnology Corporation SEC filings (Ticker: PDSB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech is tough: every 10-K details R&D burn, every 8-K flags trial milestones, and each Form 4 signals how insiders view the data. PDS Biotechnology’s Versamune immunotherapy pipeline makes those documents even denser, with pages of scientific terminology and partnership terms. Investors ask, “Where can I find the PDS Biotechnology quarterly earnings report 10-Q filing?� or “How do the latest PDS Biotechnology insider trading Form 4 transactions affect valuation?� We surface the answers immediately.
Stock Titan’s AI reads each filing the moment it hits EDGAR, then delivers line-by-line explanations in plain English. You’ll see PDS Biotechnology Form 4 insider transactions real-time, concise tables summarizing R&D expense trends, and straightforward callouts for 8-K material events. Our summaries cut through legal language so PDS Biotechnology SEC filings explained simply becomes reality. Want the PDS Biotechnology annual report 10-K simplified? One click shows Versamune trial timelines, patent cliffs, and liquidity analysis. For deeper context, a side panel is dedicated to understanding PDS Biotechnology SEC documents with AI and source links.
Beyond summaries, we connect filing types to the questions professionals actually ask. The proxy statement executive compensation section links CEO pay to clinical milestones; the PDS Biotechnology earnings report filing analysis tracks quarter-over-quarter cash use; insider data surfaces PDS Biotechnology executive stock transactions Form 4 ahead of pivotal readouts. Use our platform to monitor PDS Biotechnology proxy statement executive compensation, compare segment spending across trials, and download spreadsheets for deeper modelling. Whether you need PDS Biotechnology 8-K material events explained or a quick refresher on clinical timelines, everything is in one place, updated instantly.
DallasNews Corporation (NASDAQ: DALN) has entered into a definitive Agreement and Plan of Merger with Hearst Media West, LLC. Destiny Merger Sub, Inc., a wholly-owned subsidiary of Hearst, will merge into DallasNews, after which DallasNews will survive as a privately-held, wholly-owned subsidiary of Hearst.
Cash consideration: each outstanding share of Series A or Series B common stock will be converted into the right to receive $14.00 in cash at closing. Shares held by the Company, Hearst or dissenting shareholders are excluded.
Board & shareholder process: the DallasNews board unanimously approved the transaction. Closing requires (i) two-thirds of the total voting power, (ii) two-thirds of Series A shares voting separately, and (iii) two-thirds of Series B shares voting separately. A Voting and Support Agreement signed by Robert W. Decherd and affiliates binds approximately 55.0% of the total vote (96.2% of Series B; 1.6% of Series A) to support the deal.
Key closing conditions:
- Regulatory and customary legal approvals with no injunctions.
- Company net cash of � $20 million at the effective time.
- Accuracy of representations and compliance with covenants.
Termination terms: either party may walk away if the merger is not completed by January 9 2026. DallasNews may owe Hearst a $3 million termination fee under specified circumstances, including acceptance of a superior proposal.
Executive compensation changes:
- Transaction bonuses payable at closing: CEO Grant S. Moise $1.65 million; President Mary Kathryn Murray $0.85 million.
- Amended retention letters could provide up to $1.5 million (Moise) and $1.0 million (Murray) post-closing, plus accelerated equity of $606,375 and $270,000, respectively.
- CFO Catherine G. Collins granted change-in-control severance equal to 12 months� base salary and COBRA coverage.
Governance & bylaws: the board adopted Second Amended and Restated Bylaws introducing (i) Texas Business Court as exclusive forum, (ii) jury-trial waiver on internal claims, and (iii) 3 % ownership threshold for derivative actions.
Post-closing: DallasNews� Series A Common Stock will be delisted from Nasdaq and deregistered under the Exchange Act. Hearst Communications, Inc. has provided an unconditional guarantee of all Buyer obligations, including the cash consideration.
A joint press release announcing the merger was issued on July 10 2025. A proxy statement will be filed with the SEC; shareholders are urged to review it when available.
PDS Biotechnology Corporation (NASDAQ: PDSB) filed a Form 8-K on June 25, 2025 under Item 8.01 to announce that it has updated its corporate presentation deck. The new June 2025 slide deck is furnished as Exhibit 99.1 and incorporated by reference into the filing. No financial statements, earnings figures, strategic transactions, or other material events were disclosed. Investors should review the furnished deck for any updated development timelines or clinical program highlights; however, the 8-K itself contains no additional quantitative or qualitative information.
FAQ
What is the current stock price of Pds Biotechnology Corporation (PDSB)?
What is the market cap of Pds Biotechnology Corporation (PDSB)?
What is the primary focus of PDS Biotechnology Corporation?
How does the Versamune platform work?
What types of diseases are being targeted by the Company?
How does PDS Biotechnology approach clinical trials?
What distinguishes PDS Biotechnology in the field of immuno-oncology?
How does the Company ensure scientific rigor and expertise in its trials?
What role do combination therapies play in the Company\s strategy?
How is PDS Biotechnology positioned within the competitive biotechnology landscape?
What are the potential benefits of the Company\s immunotherapy products?
